Percheron Therapeutics (AU:PER) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Percheron Therapeutics Limited (ASX: PER) has requested a trading halt on its securities as it prepares to release initial top line data from a phase IIb clinical trial of its drug avicursen for Duchenne muscular dystrophy. The halt will remain in effect until the announcement is made or normal trading resumes on December 18, 2024. Investors are keenly awaiting these results, which could have significant implications for the company’s stock performance.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.
